Remap’s ISPOR Europe 2026 Hub

Paul Craddy founded Remap Consulting in January 2014 to help clients optimise their pricing, health economics and market access outcomes.

Prior to that, Paul was Head of Diabetes for Pricing, Market Access and Health Economics for EUCAN within Takeda Pharmaceuticals. In this role, Paul was responsible for leading the franchise including managing the launch of a new diabetes therapy, providing input into R&D for pipeline products and optimising in-market products. Paul was also a member of the PMAHE management team, helping set the strategic direction of the PMAHE department.

During his time in Nycomed, Paul led the strategic pricing team responsible for global pricing decisions for Nycomed’s global brands. He was also a core member of the PMAHE integration team during the Takeda takeover, helping to design and implement the new PMAHE organisation within Takeda.

Preceding Nycomed, Paul was a PMA consultant with IMS Consulting based in Cambridge, UK. Here, he managed numerous global PMA projects across a variety of international clients, developing launch pricing strategies, creating payer value propositions & communications and managing market access reorganisations.

Paul holds a PhD in molecular biology from Edinburgh University and has a BSc Biology from Manchester University.

Nicole Lodowski has over 15 years of experience in the biopharmaceutical industry across global and US teams. Her background spans both manufacturer and strategic consultancy organisations, where she has built and led high‑performing teams and partnered closely with clients across the US and UK. She was recognised as an MM&M 40 Under 40 honouree in 2025 for her leadership and contributions to the industry.

Nicole’s diverse expertise includes market access strategy, early pipeline planning, evidence and value strategy, HEOR, value communication, payer marketing, and medical affairs. Over the past 15 years, she has supported assets across multiple therapeutic areas and throughout the product lifecycle, bringing an integrated, cross‑functional perspective to commercial access planning. Before joining Remap, Nicole held senior roles within market access and HEOR consultancies, including Petauri, Avalere Health, PRMA Consulting, and WG Group.

Nicole is based in the United States and brings both US‑specific and global market access expertise. She holds an MPH in Global Public Health from New York University and a BSc in Biomedical Sciences from Marist College (New York, US).

Charlie has 10 years of experience in the pharmaceutical industry, split between both consultancy and NICE. Prior to joining Remap Consulting, Charlie worked at a pharmaceutical market research agency and a healthcare strategy consulting company, acting as the main client lead on life science consultancy projects for companies ranging from small biotech to large global pharma. Charlie also spent over 2 years working in NICE’s technology appraisals team, where he led the development of committee materials and guidance documents across a wide range of therapy areas.

Charlie is experienced in managing pricing and market (PMA) access projects for pharmaceutical and biotech clients, including pricing and reimbursement landscape analyses, health technology assessment (HTA) dossier development, HTA scientific advice (both parallel and individual), payer advisory boards and interviews, value proposition and value dossier development, pricing strategies and training materials. Charlie has PMA expertise across a range of therapy areas and topics, including psoriasis, ulcerative colitis and Crohn’s disease, biosimilars, multiple myeloma and DLBCL.

Charlie has an MSc in Biomaterials and Tissue Engineering from University College London, and a BSc in Biological Sciences from the University of Warwick.

Lyubo is a Business Development Director with extensive experience in strategic sales, client engagement, and commercial growth across the pharmaceutical, biotech, and life sciences sectors. He has worked with leading global organisations to build strong pipelines, drive market expansion, and deliver tailored solutions to complex client needs.

Most recently, Lyubo held several senior business development roles at Cytel, where he was responsible for generating new business across EMEA, leading cross-functional sales strategies, and expanding into white space territories. His success in initiating CxO-level partnerships and exceeding sales targets was recognised with Cytel’s prestigious President’s Club award in 2023. He also played a key role in mentoring interns and advancing DEI initiatives, including organising global LGBTQ+ events.

Lyubo’s experience also includes commercial roles at STARLAB International and Appleton Woods, where he led go-to-market strategies, secured multimillion-pound portfolios, and launched impactful digital and sustainability initiatives.

Lyubo holds a First-Class Honours BSc in Business and Management from Aston University and has completed executive education in Leadership, Strategy, and Innovation at Edinburgh Napier University.

Andrea Latour is an experienced Market Access and HEOR professional, with roles in Industry (Pfizer, JnJ and AbbVie) and consulting companies (IQVIA, EY-Parthenon, Avalere Health and Vista Health), prior to Remap Consulting.

Andrea has led numerous Access & HEOR projects, teams, has spoken at several conference events and participated in and moderated panel discussions.

His expertise spans:

Market access and pricing strategy, incl new product planning/ launch sequencing, pricing strategy and research (pre and post launch), evidence generation strategy, HTA roadmapping, payer engagement and negotiation, GVD/CVD, value proposition and dissemination.

HEOR, incl model development and adaptation, HTA dossier writing, targeted literature reviews, HE evidence development, publication writing, indirect treatment comparisons.

Commercial/Strategy, incl Commercial due diligence, market entry strategy, market expansion, among others.

In his career he has covered European and APAC markets, reimbursed, self-pay and hybrid.

Andrea holds an MSc in Economics and Management of Healthcare Companies and Services from Catholic University of Sacred Heart in Italy.

In his free time he enjoys travelling extensively, scuba and free diving, eating and drinking with friends, gym, golf and many other sports and activities.

Sam is a senior analyst whose prior experience in client-orientated roles, allows him to efficiently understand clients’ needs and provide effective assistance.

Prior to joining Remap Sam completed a BSc in Biochemistry at the University of Bath before going on to obtain a distinction for his master’s degree in Biotechnology and Enterprise at the University of Manchester. Both these academic successes have helped Sam develop his primary and secondary research skills on projects in areas such as scaffold design for regenerative medicine and cancer epigenetics. From this, Sam gained valuable expertise in data analysis and is passionate about applying these skills and experiences to meet the needs of his clients.

During his time at university, Sam participated in extracurricular activities allowing him to gain experience in collaborating, coordinating, and communicating on projects to deliver a valuable outcome.

Nick is an analyst with a strong academic background in neuroscience and practical experience in pre-clinical research and market analysis. He brings expertise in data analysis, programming, and market research, making him a valuable asset to the team.

Nick recently graduated with a BSc (Hons) in Neuroscience from The University of Manchester, achieving high first-class honors. During his industrial placement at Storm Therapeutics Ltd, he gained hands-on experience in pre-clinical cancer research and led market research initiatives for new drug development, providing valuable insights into the pharmaceutical industry.

In addition to his scientific and analytical skills, Nick has demonstrated strong leadership abilities. At the Masood Entrepreneurship Centre, he successfully led a team to secure £50,000 in grant funding. His ability to interpret complex data, identify market opportunities, and contribute to strategic decision-making will support the team’s continued success.